Simply Wall St.1d agoneutral
FDA Guidance Lifts Philip Morris Smoke Free Story And Valuation DebateFDA issues new regulatory guidance that supports commercialization of Philip Morris International's ZYN Ultra and IQOS in the U.S. The agency indicates it will not prioritize enforcement against nicotine pouch and e-vapor products with accepted premarket tobacco applications. This update reduces regulatory uncertainty around NYSE:PM smoke free products and is reflected in stronger Q1 results and improved sentiment among market participants. For investors watching NYSE:PM, this FDA shift...